Asia Pacific preventive vaccines market will grow by 13.32% annually with a total addressable market cap of $114.84 billion over 2021-2026 owing to the increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 58 tables and 51 figures, this 138-page report “Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire Asia Pacific preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.

Based on Vaccine Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines

Based on Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases

Based on Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes

Based on Patient, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)